Protective effect of liposomal-amphotericin B against C. albicans infection in mice.

The efficacy of free amphotericin B (AmpB) and liposomal-amphotericin B (L-AmpB) in the protection against C. albicans infection in mice was studied. Mice injected with a single dose of L-AmpB (1-4 mg/kg) two days prior to the yeast inoculation had an increased survival time when compared to animals injected with lower doses (0.8 mg/kg) of free AmpB or L-AmpB. L-AmpB (4 mg/kg of body weight) conferred protection against the fungal infection even when administered as a single dose five days prior to the yeast inoculation. A single-dose regimen of free AmpB showed a protective effect only when administered two days prior to the inoculum. When mice were challenged with larger yeast inocula, protection was seen with L-AmpB (4 mg/kg) or with multiple doses of free AmpB (0.8 mg/kg daily x 5) and not with single doses of free AmpB. In this group of mice, only animals treated with L-AmpB were microbiologically free of infection.

[1]  J. Reuben,et al.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.

[2]  E. Hersh,et al.  Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. , 1984, The Journal of infectious diseases.

[3]  G. Lopez-Berestein,et al.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. , 1984, Biochimica et biophysica acta.

[4]  E. Hersh,et al.  Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[5]  W. Lee,et al.  Fungal infections in patients with acute leukemia. , 1982, The American journal of medicine.

[6]  G. Medoff,et al.  Influence of extracellular K+ or Mg2+ on the stages of the antifungal effects of amphotericin B and filipin , 1980, Antimicrobial Agents and Chemotherapy.

[7]  G. Medoff,et al.  Strategies in the treatment of systemic fungal infections. , 1980, The New England journal of medicine.

[8]  J. Little,et al.  Immunopotentiating effects of amphotericin B. II. Enhanced in vitro proliferative responses of murine lymphocytes. , 1979, Journal of immunology.

[9]  J. Little,et al.  Immunopotentiating effects of amphotericin B. I. Enhanced contact sensitivity in mice. , 1979, Journal of immunology.

[10]  J. Cuttner,et al.  Fungal infection in acute leukemia , 1972, Cancer.

[11]  E. Gehan A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[12]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[13]  E. Hersh,et al.  Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice. , 1984, International journal of nuclear medicine and biology.

[14]  G. Lopez-Berestein,et al.  Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. , 1984, Cancer drug delivery.

[15]  E. Hersh,et al.  Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. , 1983, Cancer drug delivery.

[16]  L. Young,et al.  Aspergillosis complicating neoplastic disease. , 1973, The American journal of medicine.